Clinical Trial: TRANsplantation vs reSECTion After Conversion Therapy for Initially Unresectable Colorectal Liver Metastases

U.S., May 27 -- ClinicalTrials.gov registry received information related to the study (NCT07607873) titled 'TRANsplantation vs reSECTion After Conversion Therapy for Initially Unresectable Colorectal Liver Metastases' on May 14.

Brief Summary: The TRANSECT trial is a prospective randomized study designed to evaluate the role of liver transplantation (LT) versus radical local treatment (hepatic resection and/or ablation) in patients with initially unresectable colorectal liver metastases (CRLM) converted to resectability after conversion therapy.

Liver metastases are the leading cause of mortality in colorectal cancer patients. Although hepatic resection combined with chemotherapy remains the standard curative-intent treatment, only a mino...